Integra LifeSciences01.05.21
Integra LifeSciences Holdings Corporation, a leading global medical technology company, has completed its previously announced divestiture of its Extremity Orthopedics business to Smith+Nephew.
Smith+Nephew payed $240 million in cash for the business.
“With this divestiture, we will now be in an even stronger position to capitalize on our core products and technologies in neurosurgery and regenerative medicine, and provide greater value to our customers and shareholders,” said Peter Arduini, president and CEO, Integra LifeSciences. “We want to thank the orthopedics team for their contributions to Integra’s success and wish them all the best for their future.”
Piper Sandler & Co. is serving as financial advisor and Morgan, Lewis & Bockius LLP is acting as legal advisor to Integra.
Smith+Nephew payed $240 million in cash for the business.
“With this divestiture, we will now be in an even stronger position to capitalize on our core products and technologies in neurosurgery and regenerative medicine, and provide greater value to our customers and shareholders,” said Peter Arduini, president and CEO, Integra LifeSciences. “We want to thank the orthopedics team for their contributions to Integra’s success and wish them all the best for their future.”
Piper Sandler & Co. is serving as financial advisor and Morgan, Lewis & Bockius LLP is acting as legal advisor to Integra.